HRP20180481A2 - Ciljana modifikacija faktora viii - Google Patents

Ciljana modifikacija faktora viii

Info

Publication number
HRP20180481A2
HRP20180481A2 HRP20180481AA HRP20180481A HRP20180481A2 HR P20180481 A2 HRP20180481 A2 HR P20180481A2 HR P20180481A A HRP20180481A A HR P20180481AA HR P20180481 A HRP20180481 A HR P20180481A HR P20180481 A2 HRP20180481 A2 HR P20180481A2
Authority
HR
Croatia
Prior art keywords
fviii
site directed
directed modification
factor viii
polyethylene glycol
Prior art date
Application number
HRP20180481AA
Other languages
English (en)
Inventor
Clark Q Pan
John E. Murphy
Baisong Mei
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180481(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HRP20180481A2 publication Critical patent/HRP20180481A2/hr
Publication of HRP20180481B1 publication Critical patent/HRP20180481B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Ovaj izum se odnosi na muteine faktora VIII koji su kovalentno vezani, na predodređenom mjestu koje nije N-terminalni amin, za jedan ili više biokompatibilnih polimera kao što je polietilen glikol. Mutein konjugati zadržavaju prokoagulantno djelovanje faktora VIII te imaju poboljšane farmakokinetičke značajke.
HRP20180481AA 2004-11-12 2005-11-14 Ciljana modifikacija faktora viii HRP20180481B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (2)

Publication Number Publication Date
HRP20180481A2 true HRP20180481A2 (hr) 2018-06-29
HRP20180481B1 HRP20180481B1 (hr) 2022-02-18

Family

ID=36337298

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180481AA HRP20180481B1 (hr) 2004-11-12 2005-11-14 Ciljana modifikacija faktora viii
HRP20070268AA HRP20070268B1 (hr) 2004-11-12 2007-06-08 Ciljana modifikacija faktora viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20070268AA HRP20070268B1 (hr) 2004-11-12 2007-06-08 Ciljana modifikacija faktora viii

Country Status (32)

Country Link
US (4) US7632921B2 (hr)
EP (9) EP3153181A1 (hr)
JP (5) JP2008524117A (hr)
KR (7) KR20180110192A (hr)
CN (6) CN103102406B (hr)
AU (1) AU2005304622B2 (hr)
BR (2) BRPI0517795B8 (hr)
CA (1) CA2586379C (hr)
CY (3) CY1119292T1 (hr)
DK (3) DK2371856T3 (hr)
ES (4) ES2930159T3 (hr)
FR (1) FR19C1031I2 (hr)
HK (3) HK1117875A1 (hr)
HN (1) HN2007015683A (hr)
HR (2) HRP20180481B1 (hr)
HU (5) HUE033776T2 (hr)
IL (3) IL182903A (hr)
LT (5) LT3130601T (hr)
LU (1) LUC00118I2 (hr)
MA (1) MA29663B1 (hr)
MX (2) MX2007005466A (hr)
NL (1) NL300989I2 (hr)
NO (3) NO20210454A1 (hr)
NZ (1) NZ555032A (hr)
PH (2) PH12014500352A1 (hr)
PL (3) PL1824988T3 (hr)
PT (4) PT1824988T (hr)
RU (1) RU2423380C2 (hr)
SI (4) SI3130601T1 (hr)
UA (1) UA95225C2 (hr)
WO (1) WO2006053299A2 (hr)
ZA (1) ZA200703696B (hr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
KR101100059B1 (ko) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
ES2572779T3 (es) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
PL1824988T3 (pl) 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2213733A3 (en) * 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
CN104059155A (zh) 2008-05-16 2014-09-24 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
US20110286988A1 (en) * 2008-06-04 2011-11-24 Bayer Healthcare Llc FVIII Muteins for Treatment of Von Willebrand Disease
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
WO2010045568A1 (en) * 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
CA2740793A1 (en) * 2008-11-03 2010-06-03 Haiyan Jiang Method for the treatment of hemophilia
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
CN102369209B (zh) * 2009-03-20 2015-06-10 韩美科学株式会社 制备特异性位点生理活性多肽结合物的方法
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
CN102741422B (zh) * 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
CN102791285A (zh) 2009-12-06 2012-11-21 比奥根艾迪克依蒙菲利亚公司 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
WO2011103531A1 (en) * 2010-02-21 2011-08-25 Bayer Healthcare Llc Method for Activation and Conjugation of Biomolecules
AU2011239434B2 (en) 2010-04-15 2015-04-30 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
WO2012006623A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
JP5922141B2 (ja) 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
CN103282045A (zh) * 2010-12-16 2013-09-04 诺沃—诺迪斯克有限公司 因子viii水溶液
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
WO2012166622A1 (en) * 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2729161B1 (en) 2011-07-08 2018-12-19 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
KR20140070612A (ko) 2011-09-23 2014-06-10 노보 노르디스크 에이/에스 신규 글루카곤 유사체
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP2666782A1 (en) 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
PT3666283T (pt) 2013-03-15 2022-09-13 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
AU2014237111B2 (en) * 2013-03-15 2018-06-21 Bayer Healthcare Llc Recombinant factor VIII formulations
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3760639A1 (en) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionic polymer conjugates
WO2015059121A1 (en) * 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
KR101908074B1 (ko) * 2014-01-20 2018-10-15 옥타파마 아게 개선된 FVIII:C/FVIII:Ag의 비를 갖는 인자 VIII의 제조방법
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
JP7058940B2 (ja) 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド 凍結乾燥第ｉｘ因子製剤
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
CA2945390A1 (en) 2014-04-10 2015-10-15 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106659771B (zh) 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3265483B1 (en) 2015-03-06 2019-12-11 CSL Behring Lengnau AG Modified von willebrand factor having improved half-life
ES2774011T3 (es) 2015-05-22 2020-07-16 CSL Behring Lengnau AG Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
BR112018013861A2 (pt) 2016-01-07 2018-12-18 Csl Behring Recombinant Facility Ag polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
US20230151078A1 (en) * 2016-06-24 2023-05-18 Mogam Instiitute For Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
DK3538134T3 (da) 2016-11-11 2022-02-07 CSL Behring Lengnau AG Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
JP2020504084A (ja) 2016-11-16 2020-02-06 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 赤血球標的化第ｖｉｉｉ因子およびその使用方法
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
MA52630A (fr) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc Procédés de traitement de l'hémophilie a
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
CA3159985A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995011987A1 (en) 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
AU691111B2 (en) * 1995-06-21 1998-05-07 Google Technology Holdings LLC Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2262994A1 (en) * 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
PT1129186E (pt) 1998-11-10 2007-12-07 Sanquin Bloedvoorziening Um polipéptido factor viii com actividade de factor viii-c
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
WO2002060951A2 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP1373493B1 (en) * 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Coagulation factor vii derivative
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
ES2319745T3 (es) 2001-10-05 2009-05-12 Expression Therapeutics, Llc Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso.
CN1646564A (zh) 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CA2509260C (en) 2002-12-31 2012-10-02 Nektar Therapeutics Al, Corporation Maleamic acid polymer derivatives and their bioconjugates
DE602004029646D1 (en) 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
SI1596887T1 (sl) * 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (en) 2003-12-03 2010-04-07 University of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
PL1824988T3 (pl) 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
PL2363414T3 (pl) 2022-09-05
EP2363414B1 (en) 2022-05-18
LT1824988T (lt) 2017-10-25
SI1824988T1 (sl) 2017-11-30
KR20120136413A (ko) 2012-12-18
DK2371856T3 (en) 2022-08-08
RU2007121517A (ru) 2008-12-20
US7632921B2 (en) 2009-12-15
HUE033776T2 (en) 2018-01-29
EP2371856A3 (en) 2012-03-14
EP2371856A2 (en) 2011-10-05
PH12014500352B1 (en) 2015-07-20
IL182903A0 (en) 2007-08-19
HK1182121A1 (en) 2013-11-22
BRPI0517795B1 (pt) 2020-03-31
MX2007005466A (es) 2007-10-19
KR20140091618A (ko) 2014-07-21
LUC00118I1 (hr) 2019-05-13
KR101468345B1 (ko) 2014-12-03
BR122016022033B8 (pt) 2021-05-25
EP3130601B1 (en) 2020-07-15
EP1824988B1 (en) 2017-04-19
LT2371856T (lt) 2022-08-25
CN105753968A (zh) 2016-07-13
KR20130036780A (ko) 2013-04-12
EP2371856B1 (en) 2022-05-18
KR20160105928A (ko) 2016-09-07
JP6559642B2 (ja) 2019-08-14
EP2772500A1 (en) 2014-09-03
CA2586379C (en) 2012-04-03
KR101654011B1 (ko) 2016-09-05
CA2586379A1 (en) 2006-05-18
FR19C1031I1 (hr) 2019-06-28
US20160051633A1 (en) 2016-02-25
CN107082806A (zh) 2017-08-22
BRPI0517795B8 (pt) 2021-05-25
WO2006053299A2 (en) 2006-05-18
KR20180110192A (ko) 2018-10-08
JP6487895B2 (ja) 2019-03-20
NO344606B1 (no) 2020-02-10
EP3243833A1 (en) 2017-11-15
JP6109523B2 (ja) 2017-04-05
PL1824988T3 (pl) 2018-01-31
KR20140019489A (ko) 2014-02-14
KR101904630B1 (ko) 2018-10-04
PT2363414T (pt) 2022-08-04
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
EP3323829B1 (en) 2020-07-15
IL234433B (en) 2019-11-28
JP2017105773A (ja) 2017-06-15
EP3243834A1 (en) 2017-11-15
PT2371856T (pt) 2022-08-12
AU2005304622B2 (en) 2012-03-29
CY1123384T1 (el) 2021-12-31
CN101124331A (zh) 2008-02-13
WO2006053299A3 (en) 2006-08-24
JP2017101028A (ja) 2017-06-08
LT3130601T (lt) 2020-09-10
CY1119292T1 (el) 2018-02-14
NL300989I2 (nl) 2019-11-28
EP3153181A1 (en) 2017-04-12
CY2019024I2 (el) 2019-11-27
JP2013067621A (ja) 2013-04-18
SI2371856T1 (sl) 2022-09-30
EP2363414A2 (en) 2011-09-07
JP2015134780A (ja) 2015-07-27
BR122016022033B1 (pt) 2021-03-02
KR101243564B1 (ko) 2013-03-27
EP2363414A3 (en) 2012-03-21
JP2008524117A (ja) 2008-07-10
PL2371856T3 (pl) 2022-08-22
NO20200044A1 (no) 2007-06-27
PH12019501613A1 (en) 2020-09-14
PT3130601T (pt) 2020-10-01
LT2363414T (lt) 2022-10-25
NL300989I1 (nl) 2019-05-22
IL232540A0 (en) 2014-06-30
HUE059193T2 (hu) 2022-10-28
HK1218718A1 (zh) 2017-03-10
CN103102406B (zh) 2015-05-27
KR101483917B1 (ko) 2015-01-16
ZA200703696B (en) 2008-08-27
SI3130601T1 (sl) 2020-11-30
BRPI0517795A (pt) 2008-10-21
US20130274445A1 (en) 2013-10-17
ES2821832T3 (es) 2021-04-27
IL182903A (en) 2014-09-30
EP2772500B1 (en) 2019-12-25
MA29663B1 (fr) 2008-08-01
CY2019024I1 (el) 2019-11-27
EP3243833B1 (en) 2020-06-17
US9364520B2 (en) 2016-06-14
NZ555032A (en) 2010-02-26
LTPA2019509I1 (lt) 2019-08-26
CN105148287A (zh) 2015-12-16
HRP20180481B1 (hr) 2022-02-18
ES2930143T3 (es) 2022-12-07
HRP20070268A2 (hr) 2007-09-30
CN103214569B (zh) 2016-12-28
US20060115876A1 (en) 2006-06-01
FR19C1031I2 (fr) 2020-06-05
AU2005304622A1 (en) 2006-05-18
IL232540A (en) 2017-08-31
NO20072997L (no) 2007-06-27
HUS1900026I1 (hu) 2022-04-28
EP1824988A2 (en) 2007-08-29
CN105148287B (zh) 2019-07-09
PH12014500352A1 (en) 2015-07-20
UA95225C2 (ru) 2011-07-25
NO345800B1 (no) 2021-08-09
EP3323829A1 (en) 2018-05-23
RU2423380C2 (ru) 2011-07-10
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
CN103214569A (zh) 2013-07-24
HRP20070268B1 (hr) 2018-04-20
HN2007015683A (es) 2011-07-11
US9096656B2 (en) 2015-08-04
CN103102406A (zh) 2013-05-15
ES2633916T3 (es) 2017-09-26
HUE050542T2 (hu) 2020-12-28
PT1824988T (pt) 2017-07-21
HK1117875A1 (en) 2009-01-23
DK1824988T3 (en) 2017-08-07
ES2930159T3 (es) 2022-12-07
LTC1824988I2 (lt) 2021-02-25
US20100081615A1 (en) 2010-04-01
HUE060016T2 (hu) 2023-01-28
CN101124331B (zh) 2013-04-24
MX350293B (es) 2017-09-04
BRPI0517795A8 (pt) 2018-12-26
EP1824988A4 (en) 2008-12-31
DK2363414T3 (da) 2022-08-08
LUC00118I2 (hr) 2019-12-27
EP3130601A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
HRP20180481A2 (hr) Ciljana modifikacija faktora viii
ATE422880T1 (de) Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
ATE479421T1 (de) Kationisches konditionierungsmittel
ATE246202T1 (de) Gcsf konjugate
BRPI0510175A (pt) composições farmacêuticas comprimidas
GEP20074016B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
DE60237986D1 (de) Polymer auf basis von konjugierten dienen, herstellungsverfahren dafür und dieses enthaltende kautschukzusammensetzungen
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
TW200635576A (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
MX2010001955A (es) Enlazadores polimericos que contienen porciones de disulfuro-piridilo.
CY1105847T1 (el) Γραμμικες βασικες ενωσεις που εμφανιζουν δραστικοτητα ανταγωνιστη της nk-2 και σκευασματα αυτων
BR0209440A (pt) Sulfonamidas
TW200531686A (en) Pharmaceutical compositions
ATE450576T1 (de) Transparente polyamidzusammensetzungen und damit hergestellte artikel
NO20033701D0 (no) Stabilisatorsammensetning for halogenerte polymerer, deres anvendelse og polymerer omfattende slike sammensetninger
DE602005027591D1 (de) Daraus geformte artikel
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
SE9904404D0 (sv) Novel composition
NO20021573D0 (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksylkopolymerer
MY173864A (en) Site-directed modification of fviii
MY151329A (en) Site-directed modification of fviii
MY181129A (en) Site-directed modification of fviii
HRP20090547T1 (hr) Farmaceutski pripravci koji sadrže zd6474
MXPA05011430A (es) Compuestos lineares basicos antagonistas de nk-2 y formulaciones que los contienen.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181102

Year of fee payment: 14

AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20191029

Year of fee payment: 15

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201112

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211112

Year of fee payment: 17

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20221111

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20231030

Year of fee payment: 19